Wednesday, July 8, 2026

Patent intelligence · US

US 10597739

Probiotic bifidobacterium strain

granted A61KA61K35/745A61PA61P1/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 14
Applicant portfolio 158
Patent details — US 10597739
Jurisdiction
US
Status
granted
Grant date
Mar 24, 2020
Expiration
Mar 19, 2040
Claims
12
CPC classes
A61K, A61K35/745, A61P, A61P1/00
View on Google Patents ↗

Quick answer

US 10597739 (Probiotic bifidobacterium strain) is held by PrecisionBiotics Group Limited. Status: granted. Granted Mar 24, 2020. Expires Mar 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
12
CPC classes
A61K, A61K35/745, A61P, A61P1/00, A61P1/02, A61P1/04

More from PrecisionBiotics Group Limited

Related pharmaceutical patents in our USPTO index.

  1. US 12419920

    Bifidobacterium longum NCIMB 41676

    PrecisionBiotics Group Limited · Expires Sep 18, 2045

    granted
  2. US 12410418

    Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

    Precision BioSciences, Inc. · Expires Sep 4, 2045

    granted
  3. US 12351839

    Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

    Precision BioSciences, Inc. · Expires Jul 3, 2045

    granted
  4. US 12344676

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Expires Jun 26, 2045

    granted
  5. US 12336835

    Neuromodulation to target glucose transporter and/or incretin pathways

    GE Precision Healthcare LLC · Expires Jun 19, 2045

    granted
  6. US 12232492

    Disinfection of bacteriophages products using supercritical carbon dioxide

    PRECISIONBIOTIX TECHNOLOGIES INC. · Expires Feb 20, 2045

    granted
  7. US 12233135

    Therapeutic constructs for treating cancer

    PRECISION MOLECULAR INC. · Expires Feb 20, 2045

    granted
  8. US 12180463

    Lactobacillus reuteri

    PrecisionBiotics Group Limited · Expires Dec 26, 2044

    granted

Frequently asked questions

What is US patent 10597739?

US 10597739 (Probiotic bifidobacterium strain) is held by PrecisionBiotics Group Limited. Status: granted. Granted Mar 24, 2020. Expires Mar 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10597739?

PrecisionBiotics Group Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.

When does US 10597739 expire?

Our index shows an expiration date of Mar 19, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.